Pulike Biological Engineering Inc
SSE:603566
Operating Margin
Pulike Biological Engineering Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
P
|
Pulike Biological Engineering Inc
SSE:603566
|
4.3B CNY |
9%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
236.5B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
177B GBP |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
36%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.7B CHF |
32%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
25%
|
Pulike Biological Engineering Inc
Glance View
Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Pulike Biological Engineering Inc's most recent financial statements, the company has Operating Margin of 9%.
You don't have any saved screeners yet